Clinical trials: Metastatic Colorectal Cancer, completed
Metastatic Colorectal Cancer
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
- Trial name
- NCT02981524
- Testing
- CY, GVAX, Pembrolizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Colorectal Cancer
Intermittent Versus Continuous Tarceva Study
This is a randomized phase II study comprising of two treatment arms in patients who are previously untreated for metastatic or recurrent colorectal cancer.
- Trial name
- NCT01243047
- Testing
- Chemotherapy
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
MSS, RAS-mutant Colorectal Cancer
Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
This is a multicenter, open-label, Phase 1B/2 study to evaluate the safety and assess the preliminary anti-tumor activity of binimetinib administered in combination with nivolumab or nivolumab + ipilimumab in adult patients with…
- Trial name
- NCT03271047
- Testing
- binimetinib, nivolumab, ipilimumab
- Where
- 50 sites in United States, Belgium and 3 more
- Volunteers
- 75 people
- Sponsor
- Pfizer
Colorectal Neoplasms
Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial
The purpose of this study is through a phase I/II clinical trial to assess the safety and toxicity of intraperitoneally administered MOC31PE immunotoxin, given on the 1.postoperative day after cytoreductive surgery (CRS) and…
- Trial name
- ImmunoPeCa (NCT02219893)
- Testing
- MOC31PE Immunotoxin
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Colorectal Cancer
Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if irinotecan is more effective with or without oxaliplatin in treating metastatic…
- Trial name
- NCT00012389
- Testing
- irinotecan hydrochloride, oxaliplatin
- Where
- 154 sites in United States, Brazil and 5 more
- Sponsor
- Sanofi
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Colorectal Cancer
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
The primary objective of this study is to compare the effect of panitumumab versus cetuximab on overall survival (OS) for chemorefractory metastatic colorectal cancer (mCRC) among patients with wild-type Kirsten rat Sarcoma-2…
- Trial name
- NCT01001377
- Testing
- Cetuximab, Panitumumab
- Where
- 152 sites in United States, Australia and 27 more
- Volunteers
- 1,010 people
- Sponsor
- Amgen
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Colorectal Cancer
Early Biomarker With 18F-FDG PET for Treatment Optimization of Anti-EGFR Therapy in Patients With Metastatic Colorectal Cancer.
3rd line standard treatment of patients with metastatic colorectal cancer (CRC) harboring K-ras wild type consists of anti-EGFR treatment with either cetuximab or panitumumab.
- Trial name
- NCT01691391
- Testing
- (Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles
- Where
- Netherlands
- Volunteers
- 46 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Neoplasms
Risk-adapted Screening in First-degree Relatives of Patients With Colorectal Cancer
BACKGROUND: First-degree relatives of patients with colorectal cancer are at increased risk for colorectal cancer as well. Nevertheless, participation in the German national screening program stagnates at 2-3 percent per year…
- Trial name
- FAMKOL (NCT01903395)
- Testing
- Nurse-led counselling
- Where
- 33 sites in Germany
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Colorectal Cancer
An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer
This multicenter observational study will evaluate the efficacy and safety of first-line bevacizumab (Avastin) in combination with fluoropyrimidine-based chemotherapy in participants with metastatic colorectal cancer (mCRC).
- Trial name
- NCT01712347
- Testing
- Bevacizumab, Chemotherapy
- Where
- 9 sites in Taiwan
- Volunteers
- 351 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Circulating Tumor Cells and Neutrophils Count for Colorectal Metastatic Cancer
Colorectal cancer represents a major public health problem in France because of its high incidence and severe prognosis. Early stages of the disease are well know and have justified the establishment of a mass screening strategy.
- Trial name
- NCT05793775
- Where
- 2 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Metastatic Colorectal Cancer
Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)
Bevacizumab beyond progression has been proven to be safe in the community setting (BRiTE) and in the post-marketing study (BEAT), and confirmed its efficacy and safety in the first line with all regimens of chemotherapy.
- Trial name
- SAFE (NCT00862342)
- Testing
- Bevacizumab (Avastin)
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Asan Medical Center
Colorectal Cancer
A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
This study will assess the safety and pharmacokinetics of adding dulanermin to Camptosar®/Erbitux® or the FOLFIRI regimen (Camptosar®, 5-FU, and leucovorin) plus bevacizumab (only for Cohort 6 subjects who have not received prior…
- Trial name
- NCT00671372
- Testing
- FOLFIRI regimen, bevacizumab, cetuximab
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Genentech, Inc.
Colorectal Carcinoma
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
To evaluate the response rate of cetuximab plus irinotecan combination therapy in subjects with EGFR-detectable metastatic colorectal carcinoma who have documented progressive disease to irinotecan-based chemotherapy and who have…
- Trial name
- NCT00362102
- Testing
- Cetuximab
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00039273
- Testing
- panitumumab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Colorectal Cancer, Metastatic Cancer
Flt3L in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Flt3L may stimulate a person's immune system and help kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of flt3L given to patients before undergoing surgery to remove metastases from colorectal cancer.
- Trial name
- NCT00003431
- Testing
- recombinant flt3 ligand
- Where
- United States
- Sponsor
- Duke University
Patient Reported Outcome Measures, Colorectal Cancer
Predicting Disease Progression and/or Recurrence in Cancer
This is a prospective study addressing the challenge of predicting disease progression and/or recurrence in patients diagnosed with metastatic colorectal, pancreatobiliary, or esophagogastric cancer that are receiving anti-cancer…
- Conditions
- Patient Reported Outcome Measures, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer
- Trial name
- NCT04776837
- Testing
- Observational Cohort
- Where
- United States
- Volunteers
- 159 people
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer
Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer
To assess the efficacy of FOLFOX4 in combination with cetuximab, weekly and FOLFOX4 in combination with cetuximab, biweekly.
- Trial name
- CORE 2 (NCT00479752)
- Testing
- FOLFOX4 (Oxaliplatin), Cetuximab
- Where
- 24 sites in Austria, Bosnia and Herzegovina and 11 more
- Volunteers
- 151 people
- Sponsor
- Central European Cooperative Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.